Compare Abeona Therapeutics Inc (ABEO) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cadence Design Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Cadence Design Systems Inc trades at $371.23 (market cap $102.34B). The key difference: Cadence Design Systems Inc is far larger — about 274.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | CDNS | |
|---|---|---|
Market Cap | $373.32M | $102.34B |
Sector | Health | Technology |
52-Week High | $7.23 | $416.39 |
52-Week Low | $4.17 | $265.66 |
Enterprise Value | $228.22M | $104.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Cadence Design Systems (CDNS) trades at $371.06, down 0.56% on the day, with strong analyst support showing 84% buy ratings and a $395.88 consensus price target. The stock demonstrates robust fundamentals with consistent earnings beats, 86% gross margins, and 21% net income margins. Recent technical analysis shows neutral momentum with support at $370 and resistance at $380. The company benefits from AI-driven semiconductor design demand and recently announced expanded collaboration with Intel Foundry.
CDNS presents a compelling growth story with strong profitability and market positioning in EDA software. The primary investment thesis centers on sustained AI-driven demand for chip design tools, though elevated valuation multiples (P/E 87.6) require continued execution. Key risks include semiconductor cycle volatility and competitive pressures from Synopsys. Upside potential exists if the company maintains its earnings beat streak and capitalizes on AI infrastructure spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
